Clinical Trial Update: Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease [Phase 3]

View source ↗

Summary

A Phase 3 study evaluating Lecigon, an intestinal levodopa plus entacapone therapy for Parkinson's disease, is currently recruiting. The trial aims to counterac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Lecigon (levodopa-entacapone intestinal gel)

Snippet

Sponsor: University Hospital Tuebingen | Conditions: PARKINSON DISEASE (Disorder) | Phase 3 | Status: RECRUITING